Navigation Links
Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
Date:9/30/2008

and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

(Logo: http://www.newscom.com/cgi-bin/prnh/20051021/LAJACOBSEGLOGO)


'/>"/>
SOURCE Jacobs Engineering Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
2. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
5. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
6. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
7. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
8. PLC Systems Receives Delisting Notice From American Stock Exchange
9. Nephros Receives Non-Compliance Notification from AMEX
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 2Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 3Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 4Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 5Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 6Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 7Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 2Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 3Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 4Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 5Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 6Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 7Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 9Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 10Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 11China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 2China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 3China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 4China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 5China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 6China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 7
(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... a class of pharmaceuticals can both prevent and treat ... as "TSPO ligands," are currently used for certain types ... TSPO ligand in young adult mice when pathology was ... pathology was quite severe," said lead researcher Christian Pike ... reduced measures of pathology and improved behavior at both ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... MIT scientists have found a new way that DNA can ... discovering that a mold used to cast a metal tool ... shapes each showing distinct functional roles. Professor Manolis Kellis ... 1 issue of the journal Genes & Development that in ...
... Advanced Public Safety Minimizes ... Cost and Increases Accuracy -, WALL, N.J., ... International, Inc. (OTC Bulletin Board: BKYI), a leader ... Advanced Public Safety (APS), a leading provider of ...
... Cold Spring Harbor Laboratorys (CSHL) researcher Raffaella Sordella, Ph.D. ... Foundation to Conquer Lung Cancer. The two-year grant will ... class of genetic mutations that appear to be a ... of cancer deaths in the United States. The ...
Cached Biology News:MIT reports new twist in microRNA biology 2Missouri Police Department Introduces Electronic Traffic Citations 2Missouri Police Department Introduces Electronic Traffic Citations 3Missouri Police Department Introduces Electronic Traffic Citations 4Cold Spring Harbor Laboratory's lung cancer research program awarded $100,000 grant 2
Request Info...
...
...
... Inhibits several important steps of angiogenesis including proliferation, ... Also reduces intracellular reactive oxygen species (ROS) level, ... cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: